Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | CTSH | P09668 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293247 | 0.98 | CTSK (0.45) | CTSKLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13777202 | 0.92 | CTSK (0.41) | CTSKLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL23836198 | 0.83 | NAAA (0.37) | CTSKLMNANAAA | |
| SCHEMBL26572007 | 0.82 | EPHX1 (0.36) | CTSKLMNAEPHX1 | |
| SCHEMBL6149670 | 0.82 | ALDH1A1 (0.50) | CTSKLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7340018 | 0.81 | CTSK (0.56) | CTSKLMNA | |
| SCHEMBL7340009 | 0.81 | CTSK (0.56) | CTSKLMNA | |
| SCHEMBL8392753 | 0.81 | LMNA (0.50) | CTSKLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8393968 | 0.81 | LMNA (0.50) | CTSKLMNASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL18353005 | 0.80 | CTSK (0.40) | CTSKLMNASLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481676-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9434747-B2 | Methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433626-B2 | Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9409910-B2 | Azepino[4,5-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9040519-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9034865-B2 | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20130225558-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-29 | — | — | US | disclosed |
| US-20130217675-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-22 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190295-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130172320-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196839-A1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | CTSK 1125/4885LMNA 787/4885SLC1A3 3899/4885 |
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CTSK 3865/4885LMNA 3212/4885SLC1A3 157/4885 |
| US-20130190295-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | CTSK 2303/4885LMNA 4792/4885SLC1A3 497/4885 |
| US-20130172320-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CTSK 3727/4885LMNA 3987/4885SLC1A3 134/4885 |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CTSK 3865/4885LMNA 3212/4885SLC1A3 157/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CTSK 3865/4885LMNA 3212/4885SLC1A3 157/4885 |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | CTSK 2303/4885LMNA 4792/4885SLC1A3 497/4885 |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | CTSK 3495/4885LMNA 4148/4885SLC1A3 123/4885 |
| US-20130217675-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CTSK 3727/4885LMNA 3987/4885SLC1A3 134/4885 |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CTSK 3727/4885LMNA 3987/4885SLC1A3 134/4885 |
| US-20130225558-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | CTSK 3517/4885LMNA 4199/4885SLC1A3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.